Treating low DHEA in women depends almost entirely on why it is low and what symptoms it is causing. The strongest evidence supports DHEA replacement in women with adrenal insufficiency, where the hormone’s near-total absence produces measurable deficits in well-being, mood, and sexuality. For the far more common scenario of age-related decline, the picture is murkier: some benefits show up in bone density and body composition, but major medical societies still recommend against routine supplementation due to gaps in long-term safety data. What follows is a practical walkthrough of the conditions where DHEA treatment has been studied, what it can realistically do, and where the evidence runs thin.
Why DHEA Declines in Women
DHEA (dehydroepiandrosterone) is produced mainly in the adrenal glands, with smaller contributions from the ovaries. It serves as a precursor that the body converts into estrogens and androgens. In women, it is the dominant source of androgens, which matters for everything from bone health to libido. Blood levels peak in the mid-twenties and then slide downward for the rest of life. By the time a woman reaches her seventies, circulating DHEA-S (the sulfated, longer-lasting form used to measure levels) can be a fraction of what it was at age twenty-five.
The decline is not just about producing less hormone overall. Research in primates has shown that cells in the zona reticularis, the specific adrenal layer responsible for making DHEA-S, become senescent with age and show signs of exhaustion and disrupted hormone production.1PubMed. Aging induces region-specific dysregulation of hormone synthesis in the primate adrenal gland This helps explain why the drop is so steep compared with other hormones the adrenal gland makes. DHEA, DHEA-S, and testosterone all decline with age in women, though these falling levels correlate poorly with measurable signs of androgen activity in postmenopausal women, which is part of why treatment decisions are complicated.2PubMed Central. 11-Oxygenated C19 Steroids Do Not Decline With Age in Women
Besides normal aging, several medical conditions can cause unusually low DHEA. Primary adrenal insufficiency (Addison’s disease) and secondary adrenal insufficiency from pituitary problems both reduce DHEA dramatically. Long-term glucocorticoid use suppresses adrenal output. Surgical removal of the adrenal glands eliminates it entirely. These pathological causes are the situations where DHEA replacement has the clearest rationale.
Adrenal Insufficiency Is the Strongest Case for Replacement
Women with adrenal insufficiency get cortisol and aldosterone replaced as a matter of course, but DHEA is often left out. The evidence that it should be included, at least in women, is fairly persuasive. In a landmark placebo-controlled trial, daily DHEA replacement in women with adrenal insufficiency restored their initially low levels of DHEA-S, androstenedione, and testosterone to the normal range. The treatment significantly improved overall well-being, depression, and anxiety scores, and it increased the frequency of sexual thoughts, sexual interest, and satisfaction with both mental and physical aspects of sexuality.3PubMed. Dehydroepiandrosterone replacement in women with adrenal insufficiency A follow-up investigation in 24 women with primary and secondary adrenal insufficiency confirmed these results, finding that DHEA significantly improved well-being and sexuality.4PubMed. DHEA replacement in women with adrenal insufficiency–pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition
Longer-term data also look favorable. A randomized, controlled trial of extended DHEA replacement in primary adrenal insufficiency found that circulating DHEA-S and androstenedione rose significantly, with testosterone increasing to low-normal levels in women specifically. The treatment reversed ongoing bone loss at the femoral neck and enhanced total body and truncal lean mass.5PubMed Central. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial For women whose adrenal glands simply cannot make DHEA, replacement therapy fills a genuine hormonal gap and produces tangible improvements.
Intravaginal DHEA for Genitourinary Symptoms
One area where DHEA treatment has gained regulatory approval is vaginal atrophy associated with menopause. The prescription product prasterone (the pharmaceutical name for DHEA) is available as a vaginal insert and works locally: the vaginal tissue converts DHEA into estrogens and androgens on-site, which means systemic hormone levels stay relatively stable while the vaginal lining thickens and lubrication improves.
A comparative study found that prasterone was associated with substantially higher odds of improving vaginal dryness compared with radiofrequency treatment, with an adjusted odds ratio above seven.6PubMed. Intravaginal radiofrequency versus local estrogen and prasterone for genitourinary syndrome of menopause: a comparative study of clinical outcomes Because the DHEA stays local, intravaginal prasterone sidesteps many of the safety questions that hover over oral supplementation. This makes it one of the more straightforward treatments for women experiencing painful intercourse, dryness, or urinary symptoms after menopause.
Sexual Function Beyond Vaginal Symptoms
Low DHEA-S has been associated with decreased libido. In one study of women presenting with low sexual desire, about 70% were found to have decreased free testosterone and DHEA-S, suggesting a defect in adrenal hormone production in both premenopausal and postmenopausal women.7PubMed. Decreased free testosterone and dehydroepiandrosterone-sulfate (DHEA-S) levels in women with decreased libido This correlation has fueled interest in DHEA as a treatment for sexual dysfunction, but the results are uneven.
A systematic review found that DHEA improved several dimensions of sexual function, including interest, lubrication, pain, arousal, orgasm, and frequency. The benefits were most pronounced in women who already had sexual dysfunction, particularly those who were perimenopausal or postmenopausal.8PubMed. The effects of dehydroepiandrosterone on sexual function: a systematic review However, not every trial tells the same story. A randomized trial that specifically enrolled postmenopausal women with low libido found that 50 mg/day of oral DHEA for 26 weeks produced no significant improvements in sexual function compared with placebo.9PubMed. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido
The divergence between these findings likely reflects who is being treated. Women with documented adrenal insufficiency or severe hormonal deficits tend to respond more clearly than otherwise healthy postmenopausal women whose DHEA is simply lower than it used to be. If your low libido coincides with very low androgen levels and no other explanation, a trial of DHEA might be reasonable, but expectations should be calibrated: it is not a reliable fix for low desire in the general postmenopausal population.
Bone Density and Fracture Risk
Bone health is one of the more consistent bright spots in DHEA research. A genetic analysis using Mendelian randomization found that higher endogenous DHEA-S levels were causally linked to greater lumbar spine bone mineral density in women, with a roughly 30% lower risk of forearm fractures for each standard-deviation increase in DHEA-S.10The Journal of Clinical Endocrinology & Metabolism. Endogenous DHEAS Is Causally Linked With Lumbar Spine Bone Mineral Density and Forearm Fractures in Women That study drew on both genetic evidence and a pooled analysis of four clinical trials showing that DHEA treatment increases lumbar spine BMD in women.
Clinical trials bear this out. In a placebo-controlled study of postmenopausal women on glucocorticoids, DHEA supplementation produced a significant increase in bone mineral density at both the lumbar spine and femoral neck after six to twelve months of treatment.11Advances in Medical Sciences. Effect of DHEA supplementation on serum IGF-1, osteocalcin, and bone mineral density in postmenopausal, glucocorticoid-treated women Randomized trials in older adults with low DHEA-S levels have found that 50 mg of daily oral DHEA significantly improved BMD in the total hip, trochanter, and shaft regions, with women experiencing a greater increase in lumbar spine BMD than men.12PubMed Central. Dehydroepiandrosterone and Bone Health: Mechanisms and Insights For women already at risk of osteoporosis, this is a meaningful effect, though it does not replace standard osteoporosis treatments.
Body Composition
A meta-analysis of randomized trials found that DHEA supplementation did not change overall body weight or BMI but did modestly increase lean body mass and decrease fat mass as a percentage.13Steroids. The effects of dehydroepiandrosterone (DHEA) supplementation on body composition and blood pressure: A meta-analysis of randomized clinical trials The effects are small enough that the same meta-analysis noted debate about whether they translate into any clinical benefit. You would not notice these changes on a scale.
Where DHEA may matter more is in combination with exercise. A study of elderly men and women found that DHEA alone for six months did not significantly increase strength or muscle volume. But when participants also did heavy resistance training, those on DHEA gained more muscle mass and strength than those training on placebo. The mechanism appeared to involve an increase in insulin-like growth factor concentration triggered by DHEA.14PubMed. DHEA enhances effects of weight training on muscle mass and strength in elderly women and men If you are already strength training and have low DHEA, supplementation might amplify your results modestly. If you are not exercising, the body-composition effects of DHEA alone are unlikely to be noticeable.
Fertility and Diminished Ovarian Reserve
DHEA supplementation has attracted attention in fertility clinics, particularly for women with diminished ovarian reserve who are pursuing IVF. Early evidence and animal data suggested that DHEA could promote follicle growth and reduce the rate of follicle loss.15PubMed Central. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR) A meta-analysis of available studies found that clinical pregnancy rates improved significantly in women pretreated with DHEA. However, when the analysis was restricted to only the randomized controlled trials, the improvement in pregnancy rates was no longer statistically significant.16PubMed. The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis
That distinction matters. Observational and lower-quality studies can overestimate treatment effects because women who take DHEA might differ from those who do not in ways that affect outcomes. A review of the published data concluded that the uncertainty warranted well-designed multicenter randomized trials and cautioned that the absence of major side effects should not be treated as an argument for using DHEA outside of proper evidence.17PubMed. Dehydroepiandrosterone (DHEA) supplementation and IVF outcome in poor responders Many fertility specialists do offer DHEA to poor responders, and some women report subjectively better cycles, but this remains an area where enthusiasm has outpaced proof.
Mood and Cognition
In women with adrenal insufficiency, DHEA replacement consistently improves depression and anxiety scores, as noted in the trials discussed above. Outside of adrenal insufficiency, the story fragments. While studies have found positive correlations between DHEA-S levels and global cognition in women, and particularly with working memory, attention, and verbal fluency, the correlation does not mean that supplementing DHEA restores those functions.18Clinical Practice & Epidemiology in Mental Health. Dehydroepiandrosterone, Its Sulfate and Cognitive Functions In fact, supplementation trials have generally failed to improve cognitive performance and in some cases appeared to worsen it.
One study specifically analyzing the mechanisms found that DHEA administration in postmenopausal women increased cortisol levels at several points during the day, and that higher DHEA-S levels at the end of treatment were negatively associated with cognitive performance. The researchers concluded that exogenous DHEA may have a direct negative effect on cognition, not mediated by cortisol.19PubMed. Dhea supplementation and cognition in postmenopausal women This is one of the clearer cautionary findings in the DHEA literature: a hormone that correlates with better brain function when your body makes it naturally does not necessarily help when you swallow it as a supplement. If cognitive decline or brain fog is your primary concern, DHEA supplementation is not supported by current evidence and might work against you.
Oral Versus Topical Delivery
DHEA can be taken as an oral capsule, applied as a cream or gel on the skin, or inserted vaginally (as prasterone). The route matters because it affects how the body processes the hormone. A study comparing oral and percutaneous (skin-applied) DHEA in postmenopausal women found that both routes increased androgens and DHEA-S, but oral dosing produced higher levels of downstream metabolites because the liver processes the hormone on its first pass through the digestive system. Skin application gave more stable levels across 24 hours.20PubMed. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women Neither route raised estradiol levels, which is relevant for women concerned about estrogen-sensitive conditions.
Most clinical trials have used oral doses of 25 to 50 mg per day for women. Some trials studying adrenal insufficiency have used 50 mg daily, and those looking at lupus have gone as high as 200 mg. Higher doses produce more androgenic side effects like acne and unwanted hair growth. For women interested in DHEA, starting at the lower end of the dose range and monitoring blood levels is the standard approach among clinicians who prescribe it.
Safety and Cancer Risk
Because the body converts DHEA into both estrogens and androgens, any condition that could be worsened by those hormones is a concern. On the androgenic side, acne is the most common side effect across clinical trials. Some women experience oily skin, mild facial hair growth, or deepening of the voice at higher doses, though these effects typically reverse when the supplement is stopped.
The bigger worry involves estrogen-sensitive cancers. A review of DHEA’s relationship to breast cancer risk cautioned that prolonged intake might stimulate late-stage promotion of breast tumors in postmenopausal women, and that the risk could be amplified by abdominal obesity.21PubMed. Dietary supplements of dehydroepiandrosterone in relation to breast cancer risk This does not mean DHEA causes breast cancer, but it means that women with a personal or family history of hormone-sensitive cancers should approach DHEA with considerable caution. Long-term safety data beyond a few years simply do not exist for most populations.
What the Major Guidelines Say
The Endocrine Society has published two versions of its clinical practice guideline on androgen therapy in women, and both take a conservative stance. The earlier guideline recommended against diagnosing “androgen deficiency” in women altogether, citing the absence of a well-defined clinical syndrome and the lack of normative data on testosterone and DHEA levels across the lifespan that could reliably define the disorder.22PubMed. Androgen therapy in women: an Endocrine Society Clinical Practice guideline The updated guideline reiterated the recommendation against routine use of DHEA, citing limited data on effectiveness and safety in both healthy women and those with adrenal insufficiency.23The Journal of Clinical Endocrinology & Metabolism. Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline
This does not mean that every endocrinologist avoids prescribing DHEA. The guidelines acknowledge that the data show short-term benefits in specific populations, particularly women with adrenal insufficiency and surgically menopausal women. The caution is about generalizing those results to a broader group without adequate safety follow-up. In practice, many clinicians prescribe DHEA on a case-by-case basis, especially when a woman has documented low levels and symptoms that align with what trials have shown DHEA can improve.
DHEA and Lupus
Systemic lupus erythematosus (SLE) predominantly affects women, and DHEA levels are often low in lupus patients. This prompted a series of trials testing whether DHEA supplementation could reduce disease activity or allow women to taper off corticosteroids. A large multicenter trial found that 200 mg/day of oral DHEA (prasterone) reduced flare rates by about 16 percentage points compared to placebo and significantly improved patients’ self-assessment of their disease. Among women with active disease at baseline, a significantly greater proportion of those on 200 mg were able to sustain their prednisone dose below 7.5 mg/day while maintaining disease stability.24PubMed. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial Another trial found that DHEA decreased the number of flares compared with placebo and improved patients’ global assessments.25PubMed. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial
However, a later trial in women with quiescent lupus found no benefit of 200 mg DHEA over placebo for fatigue or well-being. The belief that one was taking DHEA was actually a better predictor of improvement than whether the participant had actually received it, suggesting a strong placebo effect.26PubMed. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial The pattern across these trials suggests that DHEA may have a steroid-sparing role in women with active lupus, but it does not offer general quality-of-life improvements when the disease is already well controlled.
How Oral Contraceptives Interact With DHEA
Combined oral contraceptives suppress androgen levels, sometimes substantially. A study comparing two common pill formulations found that both reduced total and free testosterone significantly, with free testosterone dropping by roughly two-thirds or more. Adding DHEA to the contraceptive regimen restored free testosterone to baseline values without affecting the levels of sex hormone-binding globulin that the pill had raised.27Contraception. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects This finding is relevant for younger women on the pill who experience symptoms like low libido, fatigue, or low mood that may be related to suppressed androgens. While co-prescribing DHEA with oral contraceptives is not yet standard practice, the pharmacological rationale is sound and represents an area of active interest.
If you are on hormonal contraception and suspect your androgen levels are too low, a blood test for DHEA-S and free testosterone can help clarify the picture. DHEA-S is relatively stable throughout the day and less affected by the timing of your pill than other hormones, making it a practical screening test. Just keep in mind that “low” on a lab report is not the same as “pathologically low,” and not every woman with below-average levels will benefit from supplementation. The decision should weigh your symptoms, your hormone levels, any risk factors for hormone-sensitive conditions, and your clinician’s judgment about whether the limited evidence base justifies a trial of treatment.